Cyclohexylamine; CASRN 108-91-8

Human health assessment information on a chemical substance is included in the IRIS database only after a comprehensive review of toxicity data, as outlined in the IRIS assessment development process. Sections I (Health Hazard Assessments for Noncarcinogenic Effects) and II (Carcinogenicity Assessment for Lifetime Exposure) present the conclusions that were reached during the assessment development process. Supporting information and explanations of the methods used to derive the values given in IRIS are provided in the guidance documents located on the IRIS website.

STATUS OF DATA FOR Cyclohexylamine

File First On-Line 09/07/1988

<table>
<thead>
<tr>
<th>Category (section)</th>
<th>Assessment Available?</th>
<th>Last Revised</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral RfD (I.A.)</td>
<td>yes</td>
<td>09/07/1988</td>
</tr>
<tr>
<td>Inhalation RfC (I.B.)</td>
<td>not evaluated</td>
<td></td>
</tr>
<tr>
<td>Carcinogenicity Assessment (II.)</td>
<td>not evaluated</td>
<td></td>
</tr>
</tbody>
</table>

I. Chronic Health Hazard Assessments for Noncarcinogenic Effects

I.A. Reference Dose for Chronic Oral Exposure (RfD)

Substance Name — Cyclohexylamine  
CASRN — 108-91-8  
Last Revised — 09/07/1988

The oral Reference Dose (RfD) is based on the assumption that thresholds exist for certain toxic effects such as cellular necrosis. It is expressed in units of mg/kg-day. In general, the RfD is an estimate (with uncertainty spanning perhaps an order of magnitude) of a daily exposure to the human population (including sensitive subgroups) that is likely to be without an appreciable risk of deleterious effects during a lifetime. Please refer to the Background Document for an elaboration of these concepts. RfDs can also be derived for the noncarcinogenic health effects of substances that are also carcinogens. Therefore, it is essential to refer to other sources of
information concerning the carcinogenicity of this substance. If the U.S. EPA has evaluated this substance for potential human carcinogenicity, a summary of that evaluation will be contained in Section II of this file.

I.A.1. Oral RfD Summary

<table>
<thead>
<tr>
<th>Critical Effect</th>
<th>Experimental Doses*</th>
<th>UF</th>
<th>MF</th>
<th>RfD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Testicular damage</td>
<td>NOAEL: 600 ppm cyclohexylamine-HCl in diet (18 mg/kg/day)</td>
<td>100</td>
<td>1</td>
<td>2E-1 mg/kg/day</td>
</tr>
<tr>
<td>Rat Chronic Oral Study</td>
<td>LOAEL: 2000 ppm cyclohexylamine-HCl in diet (60 mg/kg/day)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Gaunt et al., 1976</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Testicular damage</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Rat Chronic Reproductive Study</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oser et al., 1976</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Conversion Factors: Investigators estimated intake of cyclohexylamine-HCl in male rats at 600 ppm at 24 mg/kg/day; thus, 24 mg/kg/day x 99.17/135.63 (ratio of mol. wt. of cyclohexylamine to cyclohexylamine-HCl) results in a dosage of cyclohexylamine of 18 mg/kg/day.

I.A.2. Principal and Supporting Studies (Oral RfD)


Groups of 48 male and 48 female Wistar rats were fed diets containing 0, 600, 2000 or 6000 ppm cyclohexylamine hydrochloride for 104 weeks (Gaunt et al., 1976). The investigators estimated ingested dosages of cyclohexylamine hydrochloride at 24, 82 and 300 mg/kg/day for males and 35, 120 and 440 mg/kg/day for females. Parameters of toxicity investigated included behavior
and appearance, body weight gain and body weights, food and water consumption, limited 
hematology, urinalysis and tests of kidney function, necropsy examination and histopathologic 
examination of a large number of tissues. Effects attributed to treatment included a dose-related 
decrease in mortality, decreased body weight gain and decreased terminal body weights. Food 
consumption was decreased at greater than or equal to 2000 ppm. Females at greater than or 
equal to 2000 ppm had elevated relative thyroid weights; males at greater than or equal to 2000 
ppm had testicular degeneration, which was severe at 6000 ppm; minor hematologic effects 
ocurred in both sexes at greater than or equal to 2000 ppm; and an increased frequency of 
pulmonary alveoli with foamy macrophages was observed in rats at 6000 ppm. The effects on 
body weight gain and body weights were observed in both sexes in all treated groups throughout 
the experiment.

In a six-generation dietary study (Oser et al., 1976), FDRL strain rats (30/sex/group) were fed 
diets of 0, 15, 50, 100 or 150 mg/kg/day of cyclohexylamine-HCl in the parental (F0) generation. 
During the course of a 24-month chronic toxicity study, all F0 rats were bred six times. 
Parameters of toxicity investigated included behavior, appearance and survival, recorded body 
weights, food consumption, histopathology and hematology, blood chemistry and urinalysis. 
There was a statistically significant decrease in the rate of body weight gain in treated males (100 
and 150 mg/kg/day groups) and treated females (greater than or equal to 50 mg/kg/day groups). 
This effect was attributed to decreased food intake. The incidence of testicular atrophy was 
statistically significant at both 50 and 150 mg/kg/day cyclohexylamine; however, the incidence 
was not elevated at 100 mg/kg/day relative to controls. There was reduced fertility in the 150 
mg/kg/day group after the 4th and 5th mating, and at 100 and 150 mg/kg/day groups, there was a 
reduced number of live young/litter and the growth rate of the pups was reduced.

I.A.3. Uncertainty and Modifying Factors (Oral RfD)

UF — The UF of 100 allows for uncertainty in the extrapolation from experimental animals to 
humans (10A) and to protect unusually sensitive individuals (10H).

MF — None

I.A.4. Additional Studies/Comments (Oral RfD)

A subchronic rat study performed by the same group of investigators found adverse effects on 
body weight gain at 2000 but not at 600 ppm cyclohexylamine hydrochloride (Gaunt et al., 
1974). Long-term (Hardy et al., 1976) and multigeneration studies (Kroes et al., 1977) in mice 
indicate that mice are less sensitive than rats to the adverse effects of cyclohexylamine. The 
chemical has not been associated with teratogenicity in rats or rabbits (Oser et al., 1976; Lorke 
and Machemer, 1983; Kennedy et al., 1969).
I.A.5. Confidence in the Oral RfD

Study — High  
Database — High  
RfD — High  

Confidence in the study is rated high because it was well-planned and conducted with adequate numbers of animals and evaluated the appropriate parameters of toxicity. Confidence in the database is high because the developmental and reproductive toxicity of cyclohexylamine has been adequately investigated. High confidence in the RfD follows.

I.A.6. EPA Documentation and Review of the Oral RfD

Other EPA Documentation — None  
Agency Work Group Review — 09/17/1987  
Verification Date — 09/17/1987  
Screening-Level Literature Review Findings — A screening-level review conducted by an EPA contractor of the more recent toxicology literature pertinent to the RfD for Cyclohexylamine conducted in September 2002 did not identify any critical new studies. IRIS users who know of important new studies may provide that information to the IRIS Hotline at hotline.iris@epa.gov or (202)566-1676.

I.A.7. EPA Contacts (Oral RfD)

Please contact the IRIS Hotline for all questions concerning this assessment or IRIS, in general, at (202)566-1676 (phone), (202)566-1749 (FAX) or hotline.iris@epa.gov (internet address).

---

I.B. Reference Concentration for Chronic Inhalation Exposure (RfC)
Substance Name — Cyclohexylamine
CASRN — 108-91-8

Not available at this time.

II. Carcinogenicity Assessment for Lifetime Exposure

Substance Name — Cyclohexylamine
CASRN — 108-91-8

Not available at this time.

III. [reserved]
IV. [reserved]
V. [reserved]

VI. Bibliography

Substance Name — Cyclohexylamine
CASRN — 108-91-8

VI.A. Oral RfD References


---

VI.B. Inhalation RfC References

None

---

VI.C. Carcinogenicity Assessment References

None
VII. Revision History

Substance Name — Cyclohexylamine
CASRN — 108-91-8

<table>
<thead>
<tr>
<th>Date</th>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>09/07/1988</td>
<td>I.A.</td>
<td>Oral RfD summary on-line</td>
</tr>
<tr>
<td>12/03/2002</td>
<td>I.A.6.</td>
<td>Screening-Level Literature Review Findings message has been added.</td>
</tr>
</tbody>
</table>

VIII. Synonyms

Substance Name — Cyclohexylamine
CASRN — 108-91-8
Last Revised — 09/07/1988

- 108-91-8
- aminocyclohexane
- Cyclohexylamine
- hexahydroaniline